On this page of StockholderLetter.com we present the latest annual shareholder letter from Generation Bio Co. — ticker symbol GBIO. Reading current and past GBIO letters to shareholders can bring important insights into the investment thesis.
2023 Annual Report
To our shareholders, Last year was transformational for Generation Bio. We achieved foundational breakthroughs leading us to focus on the development of two distinct but complementary platforms: a cell-targeted lipid nanoparticle (ctLNP) delivery system designed to selectively target previously unreachable tissues and cell types while avoiding off-target uptake, and a novel immune-quiet DNA (iqDNA) cargo that has been shown to evade the innate immune response to DNA that has held non-viral therapeutics back for decades. We are now actively optimizing these platforms and using them to build our portfolio. We believe the capabilities of our highly selective and potent ctLNP delivery system could enable in vivo delivery of therapeutics to T cell and to hematopoietic stem cell (HSC), transforming the current ex vivo treatment paradigm, which is highly complex, lengthy, and expensive, to a much simpler, shorter, and lower cost in vivo process. We are advancing a wholly owned program to address sickle cell disease and beta-thalassemia using this approach for HSCs, and we continue to develop our work with our partner Moderna to be able to name a first indication in T cells. We believe that iqDNA is ideally suited to create a durable, redosable hemophilia A therapy. Hemophilia A is the first of many disease areas where delivery of iqDNA to hepatocytes in the liver could potentially apply. We are also keenly interested in exploring the profile of iqDNA in T cells and HSCs, where we believe its unique immune-quiet profile may unlock a very large set of opportunities that require either long-term DNA expression or the insertion of large DNA sequences. To allow us to reach our critical development milestones for these platforms, we made the difficult decision last year to reshape our company, yielding a smaller yet still strong and capable team of approximately 120 scientists, engineers, and professionals. Through this process and further reductions in operational expenditures, we have extended our cash runway into the second half of 2027, which affords us time to move forward in the portfolio development process. I am so grateful to our current team, members of our organization who were impacted by our reorganization, our board, and our investors for all we have achieved and all we have ahead of us. We are well positioned and excited to reach critical development milestones for our ctLNP and iqDNA platforms, as well as important proof points for portfolio programs in T cells, HSCs, and hepatocytes this year. Thank you for your continued support as we advance our mission to unlock the full potential of genetic medicine. Sincerely, GEOFF MCDONOUGH President and Chief Excutive Officer
 • shareholder letter icon 4/24/2024 Letter Continued (Full PDF)
 • stockholder letter icon 4/26/2023 GBIO Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon GBIO Benford's Law Stock Score = 86


GBIO Shareholder/Stockholder Letter Transcript:

2023
Annual
Report

To our shareholders,
Last year was transformational for Generation Bio. We achieved
foundational breakthroughs leading us to focus on the development
of two distinct but complementary platforms: a cell-targeted lipid
nanoparticle (ctLNP) delivery system designed to selectively target
previously unreachable tissues and cell types while avoiding off-target
uptake, and a novel immune-quiet DNA (iqDNA) cargo that has been
shown to evade the innate immune response to DNA that has held
non-viral therapeutics back for decades. We are now actively
optimizing these platforms and using them to build our portfolio.
We believe the capabilities of our highly selective and potent ctLNP
delivery system could enable in vivo delivery of therapeutics to T cell
and to hematopoietic stem cell (HSC), transforming the current ex vivo
treatment paradigm, which is highly complex, lengthy, and expensive, to a much simpler, shorter, and
lower cost in vivo process. We are advancing a wholly owned program to address sickle cell disease
and beta-thalassemia using this approach for HSCs, and we continue to develop our work with our
partner Moderna to be able to name a first indication in T cells.
We believe that iqDNA is ideally suited to create a durable, redosable hemophilia A therapy.
Hemophilia A is the first of many disease areas where delivery of iqDNA to hepatocytes in the liver
could potentially apply. We are also keenly interested in exploring the profile of iqDNA in T cells and
HSCs, where we believe its unique immune-quiet profile may unlock a very large set of opportunities
that require either long-term DNA expression or the insertion of large DNA sequences.
To allow us to reach our critical development milestones for these platforms, we made the difficult
decision last year to reshape our company, yielding a smaller yet still strong and capable team of
approximately 120 scientists, engineers, and professionals. Through this process and further
reductions in operational expenditures, we have extended our cash runway into the second half of
2027, which affords us time to move forward in the portfolio development process.
I am so grateful to our current team, members of our organization who were impacted by our
reorganization, our board, and our investors for all we have achieved and all we have ahead of us.
We are well positioned and excited to reach critical development milestones for our ctLNP and iqDNA
platforms, as well as important proof points for portfolio programs in T cells, HSCs, and hepatocytes
this year.
Thank you for your continued support as we advance our mission to unlock the full potential of
genetic medicine.
Sincerely,
GEOFF MCDONOUGH
President and Chief Excutive Officer



shareholder letter icon 4/24/2024 Letter Continued (Full PDF)
 

GBIO Stockholder/Shareholder Letter (Generation Bio Co.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.